• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Biotech

Breaking news and analysis on the biotech industry — covering drug development, clinical trials, IPOs, M&A, and the companies pushing biopharma forward.

Lung model
Biotech

Endeavor Hedgehog inhibitor has potential to shake up IPF space

Endeavor solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could put IPF into reverse.
James Waldron Oct 8, 2026 9:50am
IPO

Iambic aims for $135M IPO to push cancer drugs through clinic

Oct 8, 2026 8:45am
How to Choose a Biologics CDMO 4 Criteria That Matter the Most

4 Criteria for Choosing the Right Biologics CDMO

Brought to you by Rezon Bio
10 Prospect Somerville

‘It’s just survival’: Why a third of Boston lab space sits empty

Oct 8, 2026 8:00am
shutterstock25078614631png

There Is No Such Thing as a Typical Biotech

Brought to you by Syneos Health
Three blocks displaying from left to right a person a handshake and another person

Ono pays $80M for local rights to trio of Biohaven IgG degraders

Oct 8, 2026 5:23am
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings